Lyell Immunopharma, Inc.·4

Oct 12, 4:10 PM ET

Thompson Rahsaan 4

4 · Lyell Immunopharma, Inc. · Filed Oct 12, 2022

Insider Transaction Report

Form 4
Period: 2022-10-10
Thompson Rahsaan
Chief Legal Officer
Transactions
  • Award

    Option (right to buy)

    2022-10-10+715,000715,000 total
    Exercise: $6.91Exp: 2032-10-09Common Stock (715,000 underlying)
Footnotes (1)
  • [F1]1/4 of the option shares shall vest on September 28, 2023, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION